Medical Advocates
Emtricitabine(Emtriva)
 
Journal Citations

General Reports
Diagnostics
 Resistance
 Pharmacokinetic
 Efficacy
 Adverse Events



 

  
Emtricitabine Main Page Main New/Newsworthy  Home Page      
Last Update:  July 25, 2011  
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
       
 
FULL-TEXT ARTICLE
 Low Level Determinations of Methyl Methanesulfonate and Ethyl Methanesulfonate Impurities in
Emtricitabine Active Pharmaceutical Ingredient by LC/MS/MS Using Electrospray Ionization.
 Kakadiya PR, Chandrashekhar TG, Ganguly S,  et al
Anal Chem Insights. 2011;6:21-8.
 Paper

The antiretroviral potency of emtricitabine is approximately 3-fold higher compared
to lamivudine in dual human immunodeficiency virus type 1 infection/competition
experiments in vitro.
Drogan D, Rauch P, Hoffmann D,  ET AL
Antiviral Res. 2010 Jun;86(3):312-5
 Abstract

Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.
 [No authors listed] 
Prescrire Int. 2005 Apr;14(76):54-6.
 Abstract
 
Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its
Once Daily Dosing for the Treatment of HIV Infection.
Wang LH, Begley J, St Claire RL, et al  
AIDS Res Hum Retroviruses. 2004 Nov;20(11):1173-82.
Abstract
 
Emtricitabine: A Once-Daily Nucleoside Reverse Transcriptase Inhibitor (CE) (June).
Modrzejewski KA, Herman RA.  
Ann Pharmacother. 2004 Apr 30
 Abstract
 
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.
Cahn P.
Expert Opin Investig Drugs. 2004 Jan;13(1):55-68.
 Abstract
 
Polysaccharide-based chiral phase under polar organic mode of elution in the
determination of the enantiomeric purity of emtricitabine an anti-HIV analogue nucleoside.
Cass QB, Watanabe CS, Rabi JA   
J Pharm Biomed Anal. 2003 Nov 24;33(4):581-587
 Abstract

Emtricitabine: 524W91, BW524W91, Coviracil, FTC.
 Drugs R D 2003;4(1):42-48
 Abstract\

  
Pharmacokinetics
       
 
A WEEK IN REVIEW FEATURED REPORT
Pharmacokinetic Evaluation of Emtricitabine in Combination With Other Nucleoside
Antivirals in Healthy Volunteers.
Zong J, Chittick GE, Wang LH, et al 
J Clin Pharmacol. 2007 May 25;
Abstract
 
Pharmacokinetics of Emtricitabine, Tenofovir, and GS-9137 Following Coadministration of
Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted GS-9137.
Ramanathan S, Shen G, Cheng A, Kearney BP.
J Acquir Immune Defic Syndr. 2007 Mar 29;
 Abstract
 
Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support
Its Once Daily Dosing for the Treatment of HIV Infection.
Wang LH, Begley J, St Claire RL, et al  
AIDS Res Hum Retroviruses. 2004 Nov;20(11):1173-82.
Abstract

Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily
for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091
trial).
Molina JM, Peytavin G, Perusat S, et al  
HIV Med. 2004 Mar;5(2):99-104.
Abstract
Diagnostics
       
 
Selective Determination of Antiretroviral Agents Tenofovir, Emtricitabine, and Lamivudine in Human Plasma
by a LC-MS-MS Method for a Bioequivalence Study in Healthy Indian Subjects.
 Yadav M, Singhal P, Goswami S, et al
 J Chromatogr Sci. 2010;48(9):704-13.
 Abstract

A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations
of tenofovir and emtricitabine in HIV infected patients.
D'Avolio A, Sciandra M, Siccardi M, et al  
J Chromatogr Sci. 2008 Jul;46(6):524-8.
 Abstract
Resistance
       
 
Reduced Emergence of the M184V/I Resistance Mutation When Antiretroviral-Naïve Subjects Use
Emtricitabine Versus Lamivudine in Regimens Composed of Two NRTIs Plus the NNRTI Efavirenz.
McColl DJ, Margot N, Chen SS,  et al
HIV Clin Trials. 2011 Mar-Apr;12(2):61-70
 Abstract

A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
Borroto-Esoda K, Parkin N, Miller MD.
Antivir Chem Chemother. 2007;18(5):297-300.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Differential Impact of Thymidine Analogue Mutations on Emtricitabine and Lamivudine
Susceptibility.
Ross LL, Parkin N, Gerondelis P, et al 
J Acquir Immune Defic Syndr. 2006 Oct 30;
Abstract
Efficacy
       
HBV  Indications
 
 
A WEEK-IN-REVIEW-FEATURED REPORT
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with
decompensated chronic hepatitis B liver disease.
Liaw YF, Sheen IS, Lee CM,   et al
Hepatology. 2011 Jan;53(1):62-72.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Emtricitabine, a New Antiretroviral Agent with Activity against HIV and Hepatitis B Virus.
Saag MS.
Clin Infect Dis. 2006 Jan 1;42(1):126-31.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV
trials of emtricitabine.
Mondou E, Sorbel J, Anderson J  
Clin Infect Dis. 2005 Sep 1;41(5):e45-7.
 Paper

HIV  Indications
 
A WEEK-IN-REVIEW FEATURED REPORT
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
 Anderson PL, Kiser JJ, Gardner EM, et al
J Antimicrob Chemother. 2010 Nov 30.
 Abstract

Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological
improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial.
Lafaurie M, Collin F, Bentata M, et al  
J Antimicrob Chemother. 2008 Jul 28.
 Abstract
 
Safety and efficacy of regimens containing emtricitabine in HIV-infected patients taking
highly active antiretroviral therapy.
Marconi P, Lorenzini P, Borrelli I, et al 
New Microbiol. 2006 Jul;29(3):169-75.
Abstract
 
Simplification Therapy with Once-Daily Emtricitabine, Didanosine, and Efavirenz in
HIV-1-Infected Adults with Viral Suppression Receiving a Protease Inhibitor-Based
Regimen: A Randomized Trial.
Molina JM, Journot V, Morand-Joubert L et al 
J Infect Dis. 2005 Mar 15;191(6):830-9.
 Abstract
 
Simplification Therapy with Once-Daily Emtricitabine, Didanosine, and Efavirenz in
HIV-1-Infected Adults with Viral Suppression Receiving a Protease Inhibitor-Based
Regimen: A Randomized Trial.
Molina JM, Journot V, Morand-Joubert L et al  
J Infect Dis. 2005 Mar 15;191(6):830-9.
 Abstract
 
A randomized study of emtricitabine and lamivudine in stably suppressed patients
with HIV.
Benson CA, van der Horst C, Lamarca A. et al 
AIDS. 2004 Nov 19;18(17):2269-2276.
 Abstract
 
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-
naive patients: a randomized trial.
Saag MS, Cahn P, Raffi F, et al
JAMA. 2004 Jul 14;292(2):180-9.
Abstract

Prospective randomized trial of emtricitabine versus lamivudine short-term
monotherapy in human immunodeficiency virus-infected patients.
Rousseau FS, Wakeford C, Mommeja-Marin H, et al.
J Infect Dis. 2003 Dec 1;188(11):1652-8.
 Abstract
Adverse Events
       
 
Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected
Japanese patients.
 Shirasaka T, Tadokoro T, Yamamoto Y,  et al
J Infect Chemother. 2011 Mar 3.
 Abstract

Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with
additional nucleoside reverse transcriptase inhibitors.
Venhoff N, Setzer B, Melkaoui K, Walker UA.  
Antivir Ther. 2007;12(7):1075-85.
 Abstract
   
  Disorder in Clotting Pattern after Antiretroviral Treatment with Emtricitabine in an
HIV-Positive Haemophiliac Patient.
Liras A 
Clin Drug Investig. 2007;27(12):857-859.
 Abstract

Emtricitabine Main Page Main New/Newsworthy  Home Page      

Emtricitabine Journal Citations